|
|
In conclusion, a wide variety of neurological complications affected 19.5% of HT recipients. Non-infectious causes clearly predominated, but infections still accounted or 32% of the episodes. New monoclonal induction therapies have contributed to diminished CNS opportunistic infections in our program. |
|